LON:N4P N4 Pharma (N4P) Share Price, News & Analysis GBX 0.56 +0.11 (+24.44%) As of 11:48 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About N4 Pharma Stock (LON:N4P) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get N4 Pharma alerts:Sign Up Key Stats Today's Range 0.40▼ 0.7050-Day Range 0.35▼ 0.5652-Week Range 0.35▼ 0.80Volume18.13 million shsAverage Volume1.98 million shsMarket Capitalization£4.66 millionP/E RatioN/ADividend Yield3.12%Price TargetN/AConsensus RatingN/A Company Overview N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners. N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn’s disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments. click here to visit our investor hub https://investors.n4pharma.com/ Read More Receive N4P Stock News and Ratings via Email Sign-up to receive the latest news and ratings for N4 Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. N4P Stock News HeadlinesN4 Pharma PLC reports change in major holdingsMay 25, 2025 | uk.investing.comN4 Pharma PLCDecember 29, 2024 | barrons.comOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. Then an MIT team cracked the code… dropping the cost from $63,000 to just 90 cents per gram. Now, one US-based factory is gearing up to supply the AI, aerospace, and EV industries with the one material they can’t continue to grow without. Only one company controls it, and its stock is still flying under Main Street’s radar.September 1 at 2:00 AM | True Market Insiders (Ad)N4 Pharma’s Nuvec® Platform Shows Promising In Vitro Results for IBD TreatmentDecember 12, 2024 | markets.businessinsider.comN4 Pharma Plc Share Chat (N4P)November 28, 2024 | lse.co.ukN4 Pharma PLC (N4P.AQ)September 20, 2024 | ca.finance.yahoo.comN4 Pharma strikes partnership deal for intracellular deliveryApril 26, 2024 | lse.co.ukN4 Pharma sees potential in Nuvec delivery method for cancer treatmentApril 19, 2024 | lse.co.ukSee More Headlines N4P Stock Analysis - Frequently Asked Questions How have N4P shares performed this year? N4 Pharma's stock was trading at GBX 0.54 at the start of the year. Since then, N4P stock has increased by 4.7% and is now trading at GBX 0.56. How were N4 Pharma's earnings last quarter? N4 Pharma Plc (LON:N4P) released its quarterly earnings data on Monday, June, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter. N4 Pharma had a negative trailing twelve-month return on equity of 90.68% and a negative net margin of 18,399.86%. How do I buy shares of N4 Pharma? Shares of N4P stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of N4 Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that N4 Pharma investors own include 4D pharma (DDDD), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP), Coats Group (COA), EQTEC (EQT) and genedrive (GDR). Company Calendar Last Earnings6/09/2025Today9/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:N4P CIKN/A Webwww.n4pharma.com Phone+44-1332-690061FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 0 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.63 million Net Margins-18,399.86% Pretax MarginN/A Return on Equity-90.68% Return on Assets-56.00% Debt Debt-to-Equity RatioN/A Current Ratio22.73 Quick Ratio7.28 Sales & Book Value Annual Sales£7.28 thousand Price / Sales640.04 Cash FlowGBX 0.25 per share Price / Cash Flow2.25 Book ValueGBX 0.45 per share Price / Book1.25Miscellaneous Outstanding Shares832,280,000Free FloatN/AMarket Cap£4.66 million OptionableNot Optionable Beta-0.37 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:N4P) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.